<?xml version="1.0" encoding="UTF-8"?>
<p>On 29 April 2020, Gilead Sciences, Inc. provided in a press release the preliminary results obtained within SIMPLE trial 1 on severe COVID-19 patients, as follows: (i) a similar clinical improved outcome after a 5-day or 10-day treatment with RDV; (ii) an earlier start of RDV treatment (within 10 days of symptoms onset) reduces the hospitalization duration; and (iii) a high tolerance of RDV treatment (in both experimental settings: 5-day or 10-day treatment) in most patients, but some adverse effects occasionally occurred, such as nausea (10% of the patients), acute respiratory failure (a higher percentage in the 10-day group: 10.7% versus 6%), elevated liver enzymes (ALT) values (7.3% of the patients), and stopping the treatment in 3% of the patients owing to liver damage (high enzymes values) [
 <xref rid="B57-jcm-09-02084" ref-type="bibr">57</xref>].
</p>
